Related Experiment Video
Updated: Oct 4, 2025
04:41
Knee Arthrocentesis in Adults
Published on: February 25, 2022
8.0K
Aspirin thromboprophylaxis in joint replacement surgery
Anish V Sharda1,2, Kathy Fatovic3, Kenneth A Bauer1,2
1Division of Hematology Beth Israel Deaconess Medical Center Boston Massachusetts USA.
Research and Practice in Thrombosis and Haemostasis
|February 2, 2022
Summary
Aspirin monotherapy for preventing venous thromboembolism (VTE) after joint replacement surgery showed a 1.7% risk in a real-world study. This indicates a higher VTE risk than previously reported for aspirin-only prophylaxis.
Area of Science:
- Orthopedic Surgery
- Vascular Medicine
- Pharmacology
Background:
- Aspirin is a common choice for venous thromboembolism (VTE) prevention post-joint replacement in the US.
- Limited real-world prospective data exists on VTE events with aspirin-only prophylaxis after joint replacement surgery.
Purpose of the Study:
- To estimate the incidence of VTE in patients undergoing joint replacement surgery who received aspirin-only pharmacologic prophylaxis.
- To assess the real-world risk of VTE associated with aspirin monotherapy in this patient population.
Main Methods:
- A prospective observational study was conducted.
- 350 low-risk patients undergoing total knee or total hip arthroplasty were included.
- Patients received aspirin exclusively for postoperative thromboprophylaxis.
Main Results:
- The symptomatic VTE risk was observed to be 1.7% (95% CI, 0.9%-3.3%) within 3 months.
- Only one major bleeding event was recorded.
- No instances of surgical hematomas were reported.
Conclusions:
- The real-world risk of VTE with aspirin monotherapy following joint replacement surgery appears higher than previously suggested by existing literature.
- Findings highlight the need for further investigation into thromboprophylaxis strategies in joint replacement surgery.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
44
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
44
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
688
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
688
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
975
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
975
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
268
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
268
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
659
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
659